The goal of our study was to determine whether recombinant interleukin-2 (rIL-2) could modify the recurrence pattern of chronic herpes simplex virus type 2 (HSV-2) genital infection in guinea pigs. Animals that developed symptomatic acute HSV-2 infection were distributed at 14 days after viral inoculation into several treatment groups, which were similar with respect to the severity of acute disease. Three rIL-2 dosages administered for 4 weeks in daily,subcutaneous injections were tested in this study: 5 x 103, 5 X 104, and 2.5 X 105 U. Daily observations of the animals showed a significant decrease of the incidence of new recurrent lesions with the use of 5 x 104 U of rIL-2 (rate of recurrence, 0.08, compared with 0.21 in untreated controls), whereas the other rIL-2 regimens did not affect the overall rate of recurrence. Weekly analysis of recurrences showed that treatment with 5 x 104 U of rIL-2 was effective only during the first 3 weeks of use and that 2.5 x 105 U of rIL-2 markedly decreased the rate of recurrence in the first week of treatment but not in subsequent weeks. The loss of clinical protection in both groups coincided with the production of neutralizing antibodies to rIL-2. The immune mechanisms possibly involved in the protective effect of rIL-2 in chronic HSV-2 disease were further investigated. Production of gamma interferon correlated well with clinical protection, and circulating levels dropped at the time when neutralizing antibodies to rIL-2 developed. Nonspecific cytotoxicity represented by natural killer cell and lymphokine-activated killer cell activities was also increased in the treated guinea pigs. Antibody titers and lymphocyte proliferation to herpes simplex antigen were similar in rIL-2 and placebo recipients. Finally, we found that the rIL-2-induced immune stimulation was as protective against recurrent HSV-2 disease in guinea pigs as the viral suppression achieved with acyclovir. However, the biological activity of both drugs was not additive when they were coadministered.
Interleukin-2 (IL-2) is a glycoprotein secreted by T lymphocytes upon stimulation with antigens or mitogens (10, 12) , which activates several different immune mechanisms. It has been shown to induce lymphokine-activated killer cells (LAK) (1, 13, 42) , enhance natural killer cell (NK) activity (5, 14, 15, 54, 59) , elicit gamma interferon (IFN-y) production (11, 17, 19, 35) , and stimulate B lymphocytes to generate both immunoglobulin M and immunoglobulin G (18, 32, 33, 55, 58, 62) . When administered alone or with LAK, recombinant interleukin-2 (rIL-2) has a potent antitumor effect both in mice and humans (22, 24, 29, 30, 43, 44) . It also restores immune functions, in particular those mediated by T helper cells in animals with naturally acquired or druginduced immune deficiencies (26, 40, 45, 48, 50, 57) .
In our previous studies, we have shown that human rIL-2 has a protective effect against acute herpes simplex virus type 2 (HSV-2) genital infection in guinea pigs, manifested by a decreased rate of infection, less severe acute disease, and lower mortality (61) . Protection appears to be mediated principally by NK activation (60) . Moreover, LAK production, early specific immunoglobulin G anti-HSV, and circulating IFN--y may contribute to this effect. Short-term rIL-2 administration in the acute HSV-2 infection did not seem to induce specific immune memory against HSV-2 since animals escaping acute disease failed to develop both antibodies and specific HSV-stimulated lymphocyte transformation. In addition, recurrent disease in the animals that developed intravaginally through a plastic catheter attached to a syringe and followed by insertion of a plug of Gellfoam (The Upjohn Co., Kalamazoo, Mich.). The animals were monitored daily for clinical disease, and lesions were scored as previously described (61) . At the end of the 14-day acute phase, guinea pigs similar with respect to severity of acute infection were distributed among the several groups of treatment. During the chronic phase of the disease, the animals were observed daily for 15 of recurrence in the first week of treatment, which remained stable over the next 21 days, ranging from 0.13 to 0.09. In consequence, during the last week of observation, there was no significant difference between the two treatment groups.
Immunologic observations. Humoral and cellular immune parameters were assessed at 3, 10, and 21 days of treatment in an equal number of randomly selected animals that received 5 x 104 U of rIL-2 or placebo.
HSV-2 antibodies in rIL-2-treated and control animals. The antibody titers measured by an ELISA did not differ between the two groups (Table 1) .
Specific cellular immunity to HSV-2 in rIL-2-treated and control animals. PBML from 14 animals equally distributed between placebo and rIL-2 (5 x 104 U) treatment groups were cultured in the presence of viral and cell control antigens for 6 days and assayed for the incorporation of [3H]thymidine (Table 1 ). There was no significant difference in lymphocyte transformation by HSV-2 antigens between the treated and untreated animals.
Effect of rIL-2 administration on production of circulating IFN--y. Table 1 summarizes the levels of interferon measured in the plasma of 14 randomly selected guinea pigs from both control and rIL-2-treated groups at 3, 10, and 21 days of treatment. Circulating IFN-y was detected only in the animals that received rIL-2. It is of interest that at 21 days of treatment the mean titer of IFN--y was 3 ± 2 U/ml, significantly lower than the levels detected at 3 and 10 days (40 + 10 and 38 ± 14 U/ml, respectively). The decrease in the circulating IFN--y coincided with the rise in rIL-2 antibodies and the loss of clinical protective effect of the drug against recurrent disease. Relation between rIL-2 dose and duration of its protective effect against recurrent HSV-2 disease in guinea pigs. We also compared the clinical effect of 5 x 104 U of rIL-2 with two other treatment doses: 5 x 103 and 2.5 x 105 U (Fig. 2) Fig. 1; t, death. rence rate in the four treatment groups. Control animals and recipients of 5 x 103 U of rIL-2 showed a high rate of recurrence during week 1 of treatment (0.41 and 0.32, respectively) and a three-to fourfold decrease over the next 3 weeks. Guinea pigs that received daily doses of 5 x 104 U of rIL-2 showed a significant decrease in incidence of recurrent lesions during the first 3 weeks, four to six times lower than the placebo group. However, the protective effect was lost during week 4 of treatment. In addition, the highest dose of rIL-2 significantly decreased the incidence of lesions in week 1 of treatment but did not affect the subsequent course of the disease. These data suggest that chronic administration of rIL-2 has a beneficial effect which is limited in duration and that higher doses of rIL-2 give shorter protection.
Immunogenicity of rIL-2 after chronic administration in guinea pigs. Three animals that received daily doses of 5 x 104 U of rIL-2 were tested for production of antibody to rIL-2 at 0, 3, 10, and 21 days after the initiation of treatment. The antibody titers at 3 and 10 days were 0.6 + 0.1 (mean ± standard deviation) and 0.8 + 0.2, similar to levels observed before treatment (0.15 + 0.1). However, at 21 days there was a significant production of rIL-2 antibodies, with a mean titer of 160 ± 70. Guinea pigs that received 2.5 x 105 U of rIL-2 already had elevated antibody titers after 10 days of treatment, with an average titer of 32 ± 28.
To determine whether the rIL-2 antibodies that were detected in high titers by an ELISA had neutralizing activity, fivefold dilutions of serum samples, starting at 1:2, were tested for the ability to inhibit rIL-2-generated LAK activity.
A control serum from an animal that had not received rIL-2 and was negative for rIL-2 antibodies in an ELISA was also included. The experimental conditions used for testing rIL-2-induced LAK activity were established in our previous study on LAK generation from guinea pig splenocytes (60) . The results (Fig. 3) show that LAK activity can be generated in these conditions from PBML. Also, positive sera inhibited LAK generation in a dose-dependent manner with a neutralizing titer of 1:50. The serum derived from an animal that had not received rIL-2 but that was otherwise similar with respect to age and stage of disease to the donors of the positive sera failed to inhibit LAK generation (specific P815 lysis of 62% at an effector-to-target cell ratio of 50:1). This demonstrates that rIL-2 neutralization occurred only in the presence of rIL-2 antibodies and that nonspecific serum factors were not involved in the inhibition of LAK activity.
Comparison of antiviral effect of rIL-2 and ACV on recurrent HSV-2 infection. Groups of six guinea pigs which underwent comparable acute HSV-2 genital disease were randomly assigned to one of the four following treatment regimens: ACV in the drinking water at 5 mg/ml accompanied by daily injections of 5 x 104 U of rIL-2, same ACV regimen and daily injections of excipient buffer, injections of rIL-2 alone, and injections of excipient buffer alone. The animals were monitored under blind conditions for 15 days. The incidence of new recurrences in these groups of guinea pigs is represented in Fig. 4 . The control group had an overall rate of recurrence of 0.24, significantly higher than ACV with rIL-2, ACV alone, and rIL-2 alone, which showed recurrence rates of 0.08, 0.10 and 0.12, respectively. There was no significant difference among the treatment groups that received one or two active drugs. (0); placebo alone (A). The incidence of recurrent lesions was significantly higher in untreated animals when compared with any of the drug-treated groups (P < 0.05 by Student's t test for two means), whereas no difference was observed among the treatment groups. Production of neutralizing antibodies to human rIL-2 in guinea pigs chronically treated with rIL-2. PBML from three guinea pigs were cultured in medium containing 104 U of rIL-2 per ml which was previously exposed to the indicated concentrations of positive guinea pig serum (ELISA titer of rIL-2 antibodies = 250). The LAK activity of the stimulated PBML was measured in an 18-h [3H]leucine release assay of P815, effector-to-target cell ratio = 50:1. The control was LAK activity of PBML stimulated with rIL-2 that was exposed to guinea pig serum negative in antibodies to rIL-2. Data represent mean + standard deviation of percent inhibition of LAK activity compared with that of the control.
Our results demonstrate that rIL-2 has a protective effect against recurrent HSV-2 infection in guinea pigs. Specifically, there was a two-to threefold decrease in the recurrence rate in animals that received daily doses of 5 x 104 U of rIL-2 for 28 days, compared with untreated controls. Both lower and higher doses of rIL-2 appeared to be ineffective. This finding is in accordance with our previous observations on the protective effect of rIL-2 against acute HSV-2 infection in guinea pigs, in which a similar dose response was present, with peak activity at approximately 5 x 104 U of rIL-2 per dose (61) 1986 ). The studies that documented the inability of high doses of rIL-2 to protect against acute HSV disease also showed that high doses of rIL-2 failed to stimulate cytotoxic defenses.
Other factors, such as drug immunogenicity, may also contribute to the lack of protection with high doses of rIL-2. Animals that received 5 x 104 U of rIL-2 developed neutralizing antibodies to rIL-2 after 3 weeks of treatment, whereas recipients of 2.5 x 105 U had significant antibody production after 1 week. In addition, there was a chronologic correlation between production of antibodies to rIL-2 and loss of clinical protection against HSV-2 recurrences. The immunogenicity of rIL-2 in our model may be related to the use of a human-derived protein in the guinea pigs and also to the recombinant nature of the drug. At this point, no data are available for comparison regarding antibody production from either the mice or the human studies that made use of human rIL-2.
We also observed that IFN-y production paralleled the clinical protection conferred by rIL-2 against chronic HSV-2 disease and may constitute an important parameter in rIL-2 treatment. It has been previously shown that high levels of IFN--y induced by HSV antigen in lymphocyte cultures correspond to longer intervals between herpes labialis recurrences in humans (3). In addition, IFN production is decreased immediately before and during HSV recurrence (34) . However, it is still unclear whether IFN--y has a direct antiviral effect or acts by enhancing phagocytosis and intracellular killing of macrophages (4, 21) , NK (16) , and cytotoxic T cells (28, 56) . In particular, cytotoxic T lymphocytes have been strongly implicated in host defenses against viral diseases (9, 36) and deserve further investigation in our model. We also studied the role of nonspecific cytotoxic mechanisms in mediating the protective effect of rIL-2 against chronic HSV-2 infection in guinea pigs. Both NK and LAK activities were enhanced in rIL-2 recipients throughout the treatment course. LAK-mediated lysis was restricted to animals that received rIL-2, whereas NK activity was also present in untreated controls. In fact, IFN-a induced by the viral infection may also stimulate NK activity, diminishing the relative contribution of IL-2 to this immune function. In our previous study (60) , we showed that guinea pig NK and in vitro-generated LAK are able to kill HSV-2-infected targets. Therefore, rIL-2 stimulation of these cytotoxic cells might contribute to the protective effect against clinical reactivation of HSV-2 genital infection in the guinea pigs. However, in our model, LAK generation did not seem to be the most important mediator of the rIL-2 protective effect, since LAK transfer could not reproduce rIL-2 protection against acute disease and there were also time and dose discrepancies between LAK activation and clinical protection (60) . Furthermore, LAK activity was demonstrated in the chronically treated animals at a time when clinical protection of rIL-2 had already been lost. LAK-mediated lysis can extend up to 5 days after discontinuance of rIL-2 administration (data not shown), explaining the presence of LAK activity when neutralizing antibodies to rIL-2 were being produced.
Animals that were protected by rIL-2 against recurrent disease did not show any difference in antibody titers or lymphocyte stimulation when compared with controls. This finding is in accordance with previous studies that failed to establish any correlation between antibody titers to HSV and specific lymphocyte stimulation and frequency of HSV recurrences in humans (38, 39, 41, 63) .
In the present study, we demonstrated that the protection conferred to the guinea pigs by rIL-2 immune stimulation is comparable to ACV viral suppression. However, the combination of the two drugs did not have an additive effect, which may indicate that a critical amount of viral antigen has to be presented to the host immune system for rIL-2 stimulation to be specifically directed against HSV-2 infection. On the other hand, we cannot exclude that this phenomenon may be unique to the guinea pig experimental model. Although ACV has been shown to possess a potent antiviral activity against HSV both in tissue culture (7, 46) and in human studies (2, 51) , it was only moderately effective in guinea pig acute HSV-2 infection (20, 23, 31) . Our data show that ACV partially suppressed HSV-2 recurrences in the guinea pigs, at a lower level when compared with the human trials (6, 27, 52) . This suggests that rIL-2 also might have better protective activity in humans and that the immunogenicity of this lymphokine might be less important when it is used in the species from which it is derived.
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